Lightstone Ventures — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
HealthtechMenlo Park, US
BoardMark Deem(Director)inHanson S. Gifford, III(Executive Officer, Director)
Board seatHanson S. Gifford· per SEC Form D · $1M raise · filed Feb 2023
65LAB accelerates drug discovery and therapeutic company formation by connecting academic research institutions, life science investors, and Evotec to develop novel medicines into commercial entities.
BiotechDeep TechSingapore, SG
BoardSteve Courtney(Expert in Residence)
Co-investorsClavystBioLeaps by Bayer
Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.
BiotechHealthtechMedical DevicesNijmegen, NL
Co-investorsBifNew Enterprise Associates (NEA)Novartis Venture FundYsios CapitalGilde HealthcareOost NL
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.